AI assistant
Pyxis Oncology, Inc. — Director's Dealing 2024
Nov 27, 2024
33976_dirs_2024-11-27_5ef79783-618c-4a96-913a-d391b34e55d2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Pyxis Oncology, Inc. (PYXS)
CIK: 0001782223
Period of Report: 2024-11-26
Reporting Person: Connealy Pamela Ann (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-11-26 | Common Stock | P | 5450 | $2 | Acquired | 1115743 | Indirect |
| 2024-11-26 | Common Stock | P | 83400 | $1.96 | Acquired | 1199143 | Indirect |
Footnotes
F1: These shares are held directly by the Personal Def Ben Pln Trust, a revocable trust for which the Reporting Person and their spouse are the trustees.
F2: The price reported in column 4 is a weighted-average price.These shares were purchased in multiple transactions at prices ranging from $1.93 to $1.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.